

Diacomit (stiripentol)
Effective 02/01/2020

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	Medical and Specialty Medications		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
Exceptions	Non-Specialty Medications		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029
Exceptions	N/A		

Overview

Stiripentol is an anticonvulsant medication used in conjunction with clobazam for patients with Dravet syndrome. The mechanism of the anticonvulsant effect is unknown but may be due to enhancement of GABAergic inhibitory neurotransmission.

Coverage Guidelines

- Authorization may be granted for members who are currently receiving treatment with Diacomit excluding when the product is obtained as samples or via manufacturer's patient assistance program

OR

- Authorization may be granted for members who meet all the following criteria and documentation has been provided:
 - The member is at least 2 years of age
 - The member has diagnosis of Dravet syndrome
 - The prescriber is a neurologist or consult notes from a neurology office are provided
 - Diacomit will be used in combination with clobazam
 - The member has had an inadequate response or adverse reaction to one of the following anticonvulsants or a contraindication to ALL of the following anticonvulsants:
 - Clonazepam
 - Divalproex/valproic acid
 - Ethosuximide
 - Levetiracetam
 - Phenobarbital
 - Topiramate
 - Zonisamide

Limitations

- Approvals will be granted for 36 months

References

1. Diacomit (stiripentol) [prescribing information]. Beauvais, France: Biocondex; May 2020
2. Jullien V, Chhun S, Rey E, et al. Pharmacokinetics of clobazam and N-desmethylclobazam in children with dravet syndrome receiving concomitant stiripentol and valproic Acid. *Clin Pharmacokinet* 2015; 54:527
3. Fisher JL. The effects of stiripentol on GABA(A) receptors. *Epilepsia* 2011; 52 Suppl 2:76
4. Wirrell EC, Laux L, Franz DN, et al. Stiripentol in Dravet syndrome: results of a retrospective U.S. study. *Epilepsia* 2013; 54:1595.
5. Inoue Y, Ohtsuka Y, STP-1 Study Group. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: A multicenter, open-label study in Japan. *Epilepsy Res* 2015; 113:90
6. Numis AL, Sankar R. Stiripentol. In: Pellock's pediatric epilepsy: diagnosis and therapy, Fourth edition, Pellock JM, Nordli DR Jr, Sankar R, Wheless JW (Eds), Springer Publishing Company, New York 2017. p.897

Review History

11/20/19 – Reviewed at P&T. Effective 02/01/2020

11/18/2020- Reviewed at P&T

11/16/2022 – Reviewed for Nov P&T. Separated out MH vs Comm/Exch. No clinical changes.

